The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Gilles SallesDuring ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to our Chair, Gilles Salles, from South Lyon University Hospital Complex, Lyon, FR, about the results of the L-MIND trial in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Gilles Salles discusses how the L-MIND trial assesses the efficacy of the combination of an enhanced CD19 antibody and lenalidomide for patients with R/R DLBCL. He mentioned how the duration of the response was now close to 22 months, indicating a significant benefit for patients who are often difficult to treat.
Results of the L-MIND trial in R/R DLBCL